Key regions: Brazil, India, Australia, United States, United Kingdom
Antiviral drugs have been in the market for a long time, but their importance has increased significantly in recent years due to the rise of viral infections. Oman has also been affected by this trend and the Antiviral Drugs market in Oman is developing rapidly.
Customer preferences: Customers in Oman are becoming more aware of the importance of antiviral drugs due to the increasing prevalence of viral infections. They are looking for drugs that are effective against various types of viruses and have minimal side effects. Additionally, customers prefer drugs that are affordable and easily accessible.
Trends in the market: The Antiviral Drugs market in Oman is witnessing a significant increase in demand due to the rising prevalence of viral infections. The COVID-19 pandemic has also contributed to the growth of this market. The demand for antiviral drugs has increased significantly due to the need for treatment and prevention of COVID-19. Additionally, the government of Oman has taken several measures to ensure the availability of antiviral drugs in the country.
Local special circumstances: Oman is a country with a high prevalence of infectious diseases, including viral infections. The country has a hot and humid climate, which is conducive to the growth and spread of viruses. Additionally, the country has a large expatriate population, which increases the risk of viral infections.
Underlying macroeconomic factors: The Antiviral Drugs market in Oman is expected to grow significantly in the coming years due to the increasing prevalence of viral infections and the government's efforts to ensure the availability of antiviral drugs. The country's healthcare sector is also growing rapidly, which is expected to increase the demand for antiviral drugs. Additionally, the country's economy is expected to grow in the coming years, which will increase the purchasing power of consumers and drive the growth of the Antiviral Drugs market in Oman.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
